Evidence map›Paper›PMID 34972158›Full record

ArticlePloS one2021

MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy.

David Possamaï, Laïla-Aïcha Hanafi, Angélique Bellemare-Pelletier, Katia Hamelin, Paméla Thébault, Marie-Josée Hébert, Étienne Gagnon, Denis Leclerc, Réjean Lapointe

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Antigen Presentation and Autophagy in Teleost Adaptive Immunity.International journal of molecular sciences · 2022
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

David PossamaïCentre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Laïla-Aïcha HanafiCentre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Angélique Bellemare-PelletierInstitut de Recherche en Immunologie et Cancérologie, Montréal, Québec, Canada.
Katia HamelinCentre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Paméla ThébaultCentre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Marie-Josée HébertCentre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Étienne GagnonInstitut de Recherche en Immunologie et Cancérologie, Montréal, Québec, Canada.ORCID 0000-0001-5815-9768
Denis LeclercCentre de recherche en infectiologie, Centre hospitalier universitaire de Québec, Québec, Québec, Canada.
Réjean LapointeCentre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Centre Hospitalier de l’Université de Montréal · CAInstitute for Research in Immunology and Cancer · CACentre hospitalier universitaire de Québec · CA

Funding

CIHR MOP 89833
6 · The paper itself

Abstract

Nanoparticles made of the coat protein of papaya mosaic virus (PapMV) and a single-strand RNA were previously shown to be an efficient antigen presentation system for the trigger of cellular immunity. Engineering of PapMV nano with a cytotoxic T lymphocyte epitope was previously shown activating specific T lymphocytes through a proteasome-independent major histocompatibility complex class I (MHC-I) cross-presentation. In this study, we provide new insights into the mechanism of the MHC-I cross-presentation mediated by PapMV nanoparticles. We demonstrate that PapMV nanoparticles do not require the transporter associated with antigen presentation (TAP), but rather depend on lysosome acidification and cathepsin S protease activity for presentation of the T cell epitope. We have also linked the induction of autophagy with this vacuolar MHC-I cross-presentation process. Interestingly, autophagy is induced in antigen-presenting cells after PapMV nanoparticles exposure and inhibition of autophagy reduce MHC-I cross-presentation. This study demonstrates that autophagy is associated with TAP- and proteasome-independent MHC-I cross-presentation. A deeper understanding of the autophagy-dependent MHC-I cross-presentation will be useful in designing vaccination platforms that aim to trigger an efficient cytotoxic T lymphocyte response.

Indexed as

Antigen PresentationAutophagyAntigen-Presenting CellsCathepsinsChloroquineCross-PrimingEpitopesEpitopes, T-LymphocyteHistocompatibility Antigens Class IHumansLysosomesMicroscopy, ConfocalNanoparticlesPotexvirusProtein EngineeringRNAcathepsin SCathepsinsChloroquineEpitopesEpitopes, T-LymphocyteHistocompatibility Antigens Class IRNA

Identifiers

PMID34972158
PMCPMC8719699
OpenAlexW4206137796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.